Li Fangjuan, M.D., Ph.D., Associate Chief Physician, serves as a Young Committee Member of the Radiation Therapy Professional Committee of the Shanghai Anti-Cancer Association and a member of the International Association for the Study of Lung Cancer (IASLC). She has published 5 SCI-indexed papers as the first author or corresponding author, and 1 paper in the Chinese Medical Journal series. She co-authored two monographs: *New Comprehensive Treatment of Lung Cancer* and *Essentials and Clinical Practice of Radiation Therapy for Thoracic Tumors*. She holds one utility model patent, has pioneered the stereotactic radiotherapy technique for spinal metastases from lung cancer, and participated in multiple new technologies such as "one-stop" precision radiotherapy for malignant tumors. She has frequently attended international and domestic academic conferences, including the World Conference on Lung Cancer (WCLC) and the American Society for Radiation Oncology (ASTRO) Annual Meeting. As a Sub-Investigator, she has been involved in several international multicenter clinical studies, including CA209-73L and PACIFIC5.